116 related articles for article (PubMed ID: 9275673)
1. [The expression of bcl-2, P53 and c-erbB-2 onco-proteins in breast cancer and their clinicopathological significance].
Gao L; Ding H; Deng Y
Zhonghua Bing Li Xue Za Zhi; 1996 Jun; 25(3):165-8. PubMed ID: 9275673
[TBL] [Abstract][Full Text] [Related]
2. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
Quinn CM; Ostrowski JL; Harkins L; Rice AJ; Loney DP
Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
5. p53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan.
Chen HH; Su WC; Guo HR; Chang TW; Lee WY
Jpn J Clin Oncol; 2002 Sep; 32(9):332-9. PubMed ID: 12417598
[TBL] [Abstract][Full Text] [Related]
6. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
7. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
8. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome.
Mylona E; Magkou C; Giannopoulou I; Agrogiannis G; Markaki S; Keramopoulos A; Nakopoulou L
Breast Cancer Res; 2006; 8(5):R57. PubMed ID: 17032447
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 1 aneusomy with 1p36 under-representation is related to histologic grade, DNA aneuploidy, high c-erb B-2 and loss of bcl-2 expression in ductal breast carcinoma.
Farabegoli F; Ceccarelli C; Santini D; Trerè D; Baldini N; Taffurelli M; Derenzini M
Int J Cancer; 1996 Oct; 69(5):381-5. PubMed ID: 8900371
[TBL] [Abstract][Full Text] [Related]
10. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
Pich A; Margaria E; Chiusa L
J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma.
Lee WY; Jin YT; Tzeng CC
Anticancer Res; 1996; 16(5A):3007-12. PubMed ID: 8917421
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer.
Sierra A; Castellsagué X; Escobedo A; Lloveras B; García-Ramirez M; Moreno A; Fabra A
Int J Cancer; 2000 Mar; 89(2):142-7. PubMed ID: 10754491
[TBL] [Abstract][Full Text] [Related]
13. Expression of survivin, bcl-2, P53 and bax in breast carcinoma and ductal intraepithelial neoplasia (DIN 1a).
Kayaselcuk F; Nursal TZ; Polat A; Noyan T; Yildirim S; Tarim A; Seydaoglu G
J Exp Clin Cancer Res; 2004 Mar; 23(1):105-12. PubMed ID: 15149158
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
Talley L; Chhieng DC; Bell WC; Grizzle WE; Frost AR
Biotech Histochem; 2008 Feb; 83(1):5-14. PubMed ID: 18568671
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
Sharma BK; Ray A; Kaur S; Gupta S
Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
[TBL] [Abstract][Full Text] [Related]
16. Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas.
Yang Q; Yoshimura G; Nakamura M; Nakamura Y; Suzuma T; Umemura T; Mori I; Sakurai T; Kakudo K
Anticancer Res; 2002; 22(6B):3615-9. PubMed ID: 12552965
[TBL] [Abstract][Full Text] [Related]
17. [Immunohistochemical analysis of p53 and c-erbB-2 in breast cancer].
Castiglioni T; Elsner B; Curutchet HP; Montesinos M; Debonis D
Medicina (B Aires); 1995; 55(5 Pt 1):415-20. PubMed ID: 8728771
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
[TBL] [Abstract][Full Text] [Related]
19. Significance of p53, Bcl-2, and HER-2/neu protein expression in Omani Arab females with breast cancer.
Al-Moundhri M; Nirmala V; Al-Mawaly K; Ganguly S; Burney I; Rizvi A; Grant C
Pathol Oncol Res; 2003; 9(4):226-31. PubMed ID: 14688828
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
